Nasdaq · Healthcare
Pulmonx Corp (LUNG)
As-reported financials and recent SEC filings for Pulmonx Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$90.5M
Net income
$-54.0M
Net margin
-59.7%
Diluted EPS
$-1.33
ROE
-99.8%
P/E (TTM)
—
Market cap
—
Debt / equity
0.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $90.5M | $83.8M | $68.7M | $53.7M | $48.4M |
| Gross profit | $67.1M | $62.0M | $50.8M | $39.9M | $35.6M |
| Operating income | $-53.7M | $-57.7M | $-61.9M | $-58.6M | $-47.3M |
| Net income | $-54.0M | $-56.4M | $-60.8M | $-58.9M | $-48.7M |
| Diluted EPS | $-1.33 | $-1.44 | $-1.60 | $-1.59 | $-1.35 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →8-K2026-06-04
View on EDGAR →42026-06-03
View on EDGAR →Largest Healthcare peers
Go deeper on LUNG
Search Pulmonx Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.